| |
Newsroom /
Medical
/
Medical
/
Pneumonia - Drug Pipeline Analysis and Market Forecasts to 2016
Pneumonia - Drug Pipeline Analysis and Market Forecasts to 2016
The Pneumonia Therapeutics Market is Forecast to Decline Until 2016
Hyderabad,
AP,
India
(prbd.net)
11/05/2010
"Pneumonia - Drug Pipeline Analysis and Market Forecasts to 2016"
GlobalData’s analysis suggests that the global pneumonia market was worth $1.4 billion in 2009. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 4.3% for the next seven years to reach $1 billion by 2016. The projected decline rate is primarily attributable to the patent expiries of Levaquin, Avelox and Zyvox by the end of the forecast period. Increase in the treatment seeking population, the diagnosis population and the ever-increasing development of bacterial resistance to marketed antibiotics are expected to sustain the pneumonia market.
GlobalData analyzed the current competitive landscape for pneumonia drugs and found the competition to be strong. There are several marketed products for the treatment of mild to severe pneumonia, which include cephalosoprins, macrolides, carbapenems, penicillins, floroquinolones, tetracyclines and miscellaneous antibiotics. All treatments are based on attempts to clinically cure and eradicate the pathogens. The monotherapy regimens and combination therapies have satisfactory efficacy and safety profiles. However, the patent expiries of major prescribed cephalosporins and Zyvox during the forecast period have raised concerns, meaning that the pneumonia market will become increasingly genericized. New entrants into the market will be forced to match or exceed the efficacy and safety profiles of the currently marketed products.
GlobalData analyzed the pneumonia pipeline and found it to be weak. The pipeline for pneumonia consists of 50 molecules currently in development for various disease segments. Approximately 36% of the pneumonia pipeline is accounted for by product-extensions. In Phase III alone, there are 12 product-extension molecules and five me-too molecules including cell wall synthesis inhibitors and vaccines for immunoprophylaxis. Phase III products with novel mechanisms of actions seem to be more promising for use in the treatment of pneumonia caused by resistant organisms. A weak clinical pipeline coupled with low unmet needs in the pneumonia market is expected to negatively impact the market’s growth rate during the forecast period.
GlobalData has found that the global pneumonia market is a not a lucrative market with low levels of unmet need. The market is well served with several monotherapies and combination therapies which target patients with different disease characteristics. The efficacy and safety profiles of these products have improved over the years. Although newer antimicrobials are capable of managing this potentially fatal condition, the use of “correct-spectrum” antibiotics is the key as they can reduce the development of antimicrobial resistance and maintaining efficacy for newer classes of drugs. Therefore, the pneumonia market has low levels of unmet need that can be fulfilled by products that target underserved patient populations and offer improved safety and efficacy profiles.
GlobalData, the industry analysis specialist, has released a new report, “Pneumonia - Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global pneumonia market. The report identifies the key trends shaping and driving the global pneumonia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to cause significant shifts in the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumonia sector.
visit our report store: http://www.globaldata.com/reportstore
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|